These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 16623100

  • 1. [The use of anagrelide to treat thrombocytosis in connection with the chronic myeloproliferative disease].
    Jantunen E, Penttilä K, Kuittinen T, Nousiainen T.
    Duodecim; 2006; 122(4):453-7. PubMed ID: 16623100
    [No Abstract] [Full Text] [Related]

  • 2. Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders.
    Birgegård G, Björkholm M, Kutti J, Lärfars G, Löfvenberg E, Markevärn B, Merup M, Palmblad J, Mauritzson N, Westin J, Samuelsson J.
    Haematologica; 2004 May; 89(5):520-7. PubMed ID: 15136214
    [Abstract] [Full Text] [Related]

  • 3. [Anagrelide in the treatment of essential thrombocythemia (ET) and other myeloproliferative disorders with thrombocythemia based on data from patient register in the CR].
    Penka M, Doubek M, Schwarz J, Pytlík R, Dulícek P, Kissová J, Hlusí A, Vozobulová V, Cerná O, Brychtová Y, Szotkowski T, Volková Z, Seghetová J, Schutzová M, Hadacová I, Hochová I, Voglová J, Siroký O, Belada D, Lhot'anová T, Bubeník B, Vránová M, Micaníková M, Dusek L.
    Vnitr Lek; 2006 May; 52(5):498-503. PubMed ID: 16771099
    [Abstract] [Full Text] [Related]

  • 4. Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile.
    Steurer M, Gastl G, Jedrzejczak WW, Pytlik R, Lin W, Schlögl E, Gisslinger H.
    Cancer; 2004 Nov 15; 101(10):2239-46. PubMed ID: 15476273
    [Abstract] [Full Text] [Related]

  • 5. Anagrelide: 20 years later.
    Emadi A, Spivak JL.
    Expert Rev Anticancer Ther; 2009 Jan 15; 9(1):37-50. PubMed ID: 19105705
    [Abstract] [Full Text] [Related]

  • 6. Anagrelide treatment in 52 patients with chronic myeloproliferative diseases.
    Penninga E, Jensen BA, Hansen PB, Clausen NT, Mourits-Andersen T, Nielsen OJ, Hasselbalch HC.
    Clin Lab Haematol; 2004 Oct 15; 26(5):335-40. PubMed ID: 15485463
    [Abstract] [Full Text] [Related]

  • 7. New approaches to the treatment of thrombocytosis.
    Fruchtman S.
    Clin Adv Hematol Oncol; 2003 Feb 15; 1(2):92-3. PubMed ID: 16224383
    [No Abstract] [Full Text] [Related]

  • 8. The combined use of hydroxyurea and anagrelide allows satisfactory hematologic control in patients with chronic myeloproliferative disorders and thrombocytosis: a report on 13 patients with poor tolerance to hydroxyurea monotherapy.
    D'adda M, Micheletti M, Drera M, Ferrari S, Rossi G.
    Leuk Lymphoma; 2008 Nov 15; 49(11):2216-8. PubMed ID: 19021067
    [No Abstract] [Full Text] [Related]

  • 9. Anagrelide for control of thrombocytosis due to myeloproliferative disorders.
    Harrison CN.
    Future Oncol; 2005 Oct 15; 1(5):609-18. PubMed ID: 16556037
    [Abstract] [Full Text] [Related]

  • 10. Anagrelide: a new drug for treating thrombocytosis.
    Silverstein MN, Petitt RM, Solberg LA, Fleming JS, Knight RC, Schacter LP.
    N Engl J Med; 1988 May 19; 318(20):1292-4. PubMed ID: 3362187
    [Abstract] [Full Text] [Related]

  • 11. [Anagrelide--a new drug to reduce platelets in myeloproliferative diseases].
    Bennett M.
    Harefuah; 1999 May 02; 136(9):717-20. PubMed ID: 10955097
    [No Abstract] [Full Text] [Related]

  • 12. Anagrelide-induced bone marrow changes during therapy of chronic myeloproliferative disorders with thrombocytosis. an immunohistochemical and morphometric study of sequential trephine biopsies.
    Thiele J, Kvasnicka HM, Fuchs N, Brunnbauer K, Volkwein N, Schmitt-Graeff A.
    Haematologica; 2003 Oct 02; 88(10):1130-8. PubMed ID: 14555309
    [Abstract] [Full Text] [Related]

  • 13. [Anagrelide in control of myeloproliferative thrombocythemia: long-term experiences in 6 patients].
    Burkhard R, Adam H, Widmer L, Honegger HP.
    Schweiz Med Wochenschr; 1998 Nov 14; 128(46):1808-12. PubMed ID: 9857387
    [Abstract] [Full Text] [Related]

  • 14. [The results of patients with essentials thrombocythemia and other myeloproliferation-related thrombocythemia--a report of patients treated with Thromboreductin].
    Penka M, Schwarz J, Pavlík T, Indrák K, Doubek M, Dulícek P, Pospísilová D, Kissová J, Jonásová A, Jelínková P, Hlusí A, Schutzová M, Cerná O, Brychtová Y, Nováková L, Korístek Z, Segethová J, Vozobulová V, Hadacová I, Hochová I, Voglová J, Walterová L, Bodzásová C, Dusek L.
    Vnitr Lek; 2009 Nov 14; 55(11):I-XII. PubMed ID: 20017445
    [Abstract] [Full Text] [Related]

  • 15. [Anagrelide-induced changes of megakaryopoiesis during therapy of chronic myeloproliferative disorders with thrombocythemia].
    Thiele J, Kvasnicka HM, Schmitt-Gräff A.
    Pathologe; 2002 Nov 14; 23(6):426-32. PubMed ID: 12436295
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics, bioequivalence, tolerability, and effects on platelet counts of two formulations of anagrelide in healthy volunteers and patients with thrombocythemia associated with chronic myeloproliferation.
    Petrides PE, Gisslinger H, Steurer M, Linkesch W, Krumpl G, Schüller A, Widmann R.
    Clin Ther; 2009 Feb 14; 31(2):386-98. PubMed ID: 19302911
    [Abstract] [Full Text] [Related]

  • 17. Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Anagrelide Study Group.
    Am J Med; 1992 Jan 14; 92(1):69-76. PubMed ID: 1731512
    [Abstract] [Full Text] [Related]

  • 18. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders.
    Fruchtman SM, Petitt RM, Gilbert HS, Fiddler G, Lyne A, Anagrelide Study Group.
    Leuk Res; 2005 May 14; 29(5):481-91. PubMed ID: 15755500
    [Abstract] [Full Text] [Related]

  • 19. Anagrelide is effective in treating patients with hydroxyurea-resistant thrombocytosis in patients with chronic myeloid leukemia.
    Silver RT.
    Leukemia; 2005 Jan 14; 19(1):39-43. PubMed ID: 15510207
    [Abstract] [Full Text] [Related]

  • 20. [Anagrelide--new antiplatelet drug].
    Robak T, Treliński J, Hołub A.
    Acta Haematol Pol; 1994 Jan 14; 25(4):309-15. PubMed ID: 7847031
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.